Aprea Therapeutics, Karolinska Development’s portfolio company, has announced a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumour suppressor protein p53 by APR-246.
The goal of the collaboration is to evaluate and characterise preclinical efficacy of APR-246 in combination with multiple other anti-cancer agents and across multiple tumour types. Tasha Merghoub, PhD, will be the lead investigator for the study and will conduct the research in collaboration with Jedd D. Wolchok, MD, PhD, chief of Melanoma and Immunotherapeutics Service, Department of Medicine.
“We are excited to initiate this new collaboration with Memorial Sloan Kettering,” said Christian S. Schade, president and chief executive officer of Aprea Therapeutics. “These studies will not only provide important insight into the effects of APR-246-induced p53 reactivation but also inform the rationale for novel combination therapies to be tested in future clinical trials.”
Aprea Therapeutics is a biopharmaceutical company focused in the discovery and development of novel anticancer compounds reactivating the tumour suppressor protein p53.